Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Acquisitions & Divestments (2023 - 2025)

ARS Pharmaceuticals' Change in Acquisitions & Divestments history spans 3 years, with the latest figure at $75.0 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 11.94% year-over-year to $75.0 million; the TTM value through Dec 2025 reached $307.0 million, up 18.99%, while the annual FY2025 figure was $307.0 million, 18.99% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $75.0 million at ARS Pharmaceuticals, down from $88.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $88.5 million in Q3 2025 and bottomed at $20.0 million in Q1 2023.
  • The 3-year median for Change in Acquisitions & Divestments is $62.2 million (2024), against an average of $62.5 million.
  • The largest YoY upside for Change in Acquisitions & Divestments was 175.0% in 2024 against a maximum downside of 1.67% in 2024.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $60.0 million in 2023, then rose by 11.67% to $67.0 million in 2024, then increased by 11.94% to $75.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Change in Acquisitions & Divestments are $75.0 million (Q4 2025), $88.5 million (Q3 2025), and $80.0 million (Q2 2025).